

Title (en)  
METHOD FOR EXTENDING HALF-LIFE OF PROTEIN

Title (de)  
VERFAHREN ZUR VERLÄNGERUNG DER HALBWERTSZEIT VON PROTEIN

Title (fr)  
PROCÉDÉ D'EXTENSION DE LA DEMI-VIE D'UNE PROTÉINE

Publication  
**EP 3628681 A4 20210728 (EN)**

Application  
**EP 18794624 A 20180505**

Priority  
• KR 2017004730 W 20170505  
• KR 2018005239 W 20180505

Abstract (en)  
[origin: EP3628681A2] The present invention relates to a method for prolonging the half-life of a protein, the method comprising substituting at least one lysine residue present in the amino acid sequence of the protein, and to a protein having an extended half-life. The protein of the present invention, in which the lysine residue has been substituted, remains in the human body for a long time and exhibits an excellent therapeutic effect. The protein of the present invention includes EGF, PDGFA and PDGFB, GM-CSF, FSH-alpha and FSH-beta, and ANGPT-1.

IPC 8 full level  
**C07K 14/485** (2006.01); **A61K 38/00** (2006.01); **C07K 14/49** (2006.01); **C07K 14/515** (2006.01); **C07K 14/535** (2006.01); **C07K 14/59** (2006.01)

CPC (source: EP US)  
**C07K 1/1075** (2013.01 - US); **C07K 14/485** (2013.01 - EP US); **C07K 14/49** (2013.01 - EP US); **C07K 14/515** (2013.01 - EP US); **C07K 14/535** (2013.01 - EP US); **C07K 14/59** (2013.01 - EP US); **C12N 15/63** (2013.01 - US); **A61K 38/00** (2013.01 - EP US); **C07K 2319/41** (2013.01 - EP); **C07K 2319/95** (2013.01 - EP)

Citation (search report)  
• [X] WO 2007109673 A2 20070927 - UNIV STANFORD [US], et al  
• [XI] US 2015031611 A1 20150129 - SHIN HANG-CHEOL [KR], et al  
• [XP] WO 2017086627 A1 20170526 - UBIPROTEIN CORP [KR]  
• [XII] J WANG ET AL: "Biochemical Properties of Site-Directed Mutants of Human Epidermal Growth Factor: Importance of Solvent-Exposed Hydrophobic Residues of the Amino-Terminal Domain in Receptor Binding", BIOCHEMISTRY, vol. 29, no. 263, 23 October 1990 (1990-10-23), pages 9988 - 9993, XP055756375, ISSN: 0006-2960  
• [YA] WEI JIANXIN ET AL: "A new mechanism of RhoA ubiquitination and degradation: Roles of SCFFBXL19E3 ligase and Erk2", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1833, no. 12, 18 July 2013 (2013-07-18), pages 2757 - 2764, XP028773964, ISSN: 0167-4889, DOI: 10.1016/J.BBAMCR.2013.07.005  
• [YA] MICHIE H ET AL: "Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 579, no. 18, 18 July 2005 (2005-07-18), pages 3965 - 3969, XP027697143, ISSN: 0014-5793, [retrieved on 20050718]  
• [A] Y. KRAVTSOVA-IVANTSIV ET AL: "Non-canonical ubiquitin-based signals for proteasomal degradation", JOURNAL OF CELL SCIENCE, vol. 125, no. 3, 1 February 2012 (2012-02-01), Cambridge, pages 539 - 548, XP055716083, ISSN: 0021-9533, DOI: 10.1242/jcs.093567  
• See references of WO 2018203737A2

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**EP 3628681 A2 20200401**; **EP 3628681 A4 20210728**; CN 110785429 A 20200211; JP 2020518270 A 20200625; JP 2022169770 A 20221109; JP 2022169771 A 20221109; US 2020270301 A1 20200827; WO 2018203582 A1 20181108; WO 2018203737 A2 20181108; WO 2018203737 A3 20190425

DOCDB simple family (application)  
**EP 18794624 A 20180505**; CN 201880042102 A 20180505; JP 2019560669 A 20180505; JP 2022138031 A 20220831; JP 2022138032 A 20220831; KR 2017004730 W 20170505; KR 2018005239 W 20180505; US 201816611089 A 20180505